Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antagonism of Neostigmine in Continuous Infusion of Mivacurium
NCT07524959Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of neostigmine in neuromuscular blockade (NMB) (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Time from count 2 to TOFr recovery to 0.9. Planned start May 2026; status: not yet recruiting.
02
Drugs
neostigmine
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07524959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524959.